Next Phase Newsletter

By Karen Deyo, VP of Product, Israel BD, LSN

Next Monday, December 4, the partnering platform for RESI JPM 2024 will go live. With 1000 attendees expected to participate, RESI JPM is Life Science Nation (LSN)’s largest event of the year. LSN’s partnering platform gives companies a unique opportunity to identify investors and licensing partners that are a fit for them before sending a meeting request.

Doing partnering well at a conference like RESI is time consuming, but the outcome is well worth the effort. Companies need to do their research, plan their messages (yes, more than one) ahead of time, be ready to follow up multiple times, and keep an eye out for new investors, who get added to the system every day. Make sure to check out our partnering tutorials to get all of the details on LSN’s recommended strategy for partnering!

Tuesday, December 5, 12PM ET | Partnering Tutorial – Sign Up

Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are a best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation announces ‘RESI South’ in partnership with a newly formed coalition, SELifeSci, consisting of life science associations representing Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. RESI South is expected to draw a crowd of over 500 bioscience and medtech entrepreneurs and 500 premier investors, family offices, and key executives worldwide.

RESI South 2024 will occur via a hybrid format, with March 25th being in-person at the Whitley Hotel in Atlanta, Georgia, and the 26th and 27th with virtual partnering only.

Maria Thacker-Goethe, President & CEO of Georgia Bio, stated, “The southeastern region is flourishing with innovation that needs to be showcased to the global investors and licensing partners seeking technology assets for their investment portfolios and product pipelines.” Thacker-Goethe said, “While the region is still emerging in terms of density, the Southeast region is rapidly advancing in terms of startups with game-changing, impactful technology that will be translated from the laboratory and change the lives of patients in need.”

Dennis Ford, CEO of Life Science Nation, concurred, stating, “I have seen firsthand the incredible opportunities abounding in the Southeast U.S. with a plethora of colleges, universities, and hospitals, fostering life science research and development. This is combined with an amazing array of incubators, accelerators, regional and governmental entrepreneurial programs, and world-class Bio Clusters supporting startups across all phases of development.  LSN’s global partnering network wants to tap into these seven states’ technological and innovative firepower.”

Dennis stated, “This is the golden age of Life Science, and this collaboration by top association leaders from the south is a prime example of a region ready for the world stage. LSN will bring our global investor and licensing partner network for funding and licensing opportunities invigorating this compelling region.”

LSN has built a sourcing and funding global ecosystem featuring elite early-stage technology assets and the investors, co-development, and channel partners who seek them. The international infrastructure consists of life science buyers and sellers, each with curated data profiles that are “matched up” based on the stage of development and product at LSN’s dedicated worldwide partnering events. The LSN partnering platform comprises a database of potential partners for healthcare startups across drugs, devices, diagnostics, and digital health. An education curriculum for preparing entrepreneurs for executing a global fundraising roadshow. The world-renowned RESI conference series that runs five times a year worldwide so that scientist entrepreneurs and fundraising CEOs can get out of their regions and go global.  LSN estimates it has helped over 400 startups raise over $5B over the years.

Atlanta is an ideal destination for this convening. The city’s research and development labs are attracting top talent, and keeping the city on the forefront of technology and business innovation. Host to one of the largest venture conferences in the country for the tech industry, Venture Atlanta, Atlanta is primed to welcome investors for the life sciences sector to the South.

The Southeast Life Science Alliance agrees that RESI South will fill a critical gap in access to capital for its members and the broader ecosystem. Historically, investor conferences in the region have been limited and need to meet growing ecosystem needs. The landscape of funding for early-stage biotech and MedTech is changing, and these leaders believe now is the time to welcome RESI to the South.

About Life Science Nation

Life Science Nation (LSN) has built a global partnering ecosystem featuring healthcare startups and the capital investors, co-development, and licensing partners who seek them. This partnering ecosystem consists of the LSN Global Partnering Campaign Database, Focus on Cures Accelerator, and the world-renowned Redefining Early-Stage Investments (RESI) conference series, which work closely with LSN’s global tech hub network.

About the SE Alliance

The Southeast Life Science Alliance is a coalition of independent life science associations that work to build life sciences business in their respective states. Participating organizations include BioAlabama, BioFlorida, Georgia Bio, North Carolina Bio, SCbio, Life Science Tennessee, and Virginia Bio.

Contact Erika Wu e.wu@lifesciencenation.com for startup tickets and sponsorship opportunities.

A cross-border life science investment firm focuses on investments in therapeutics, medical devices, diagnostics, and life science tools. The firm invests from its latest fund of almost $1B and currently manages over $2B AUM. In addition to investing in companies in USA, Europe, and Asia, the firm is actively involved in supporting their portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-$30 MM USD.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products, but is open to promising, earlier stage opportunities with strong clinical data. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A biotechnology company is dedicated to the development of genetic detection platforms incorporated with microarrays, Next Generation Sequencing (NGS) and big data analysis for health informatics. The core services of the firm lie upon five areas within reproductive medicine (prenatal/postnatal testing), population medicine, medical oncology, liver DNA methylation test, and scientific research services.

The firm is looking for co-development and in-licensing opportunities that are a fit for their current pipelines/business areas and is open to equity investments on a case-by-case basis. For equity investments, the check size is usually under $10M, ranging between $2M – $10M. The firm is interested in opportunities globally.

The firm looks for assets that align with their current pipelines and core services. Interested areas include in-vitro diagnostics, oncology therapeutics, reproductive and women’s health related technologies. The firm is open to working with companies in different phases of development.There are no specific requirements for the company and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with initial check sizes between 1 – 3 million USD. The firm prefers to lead/co-lead the financing rounds but is open to co-investing. The firm is focused on companies located in North America and Israel.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, The firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture subsidiary of a pharmaceutical company is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment.

The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Kendall Sq. Cambridge, MA, November 30th, 2023 — Life Science Nation (LSN), the visionary force behind the globally acclaimed Redefining Early Stage Investments (RESI) Conference Series, is thrilled to announce a strategic collaboration with Biocat, headquartered in Barcelona, Catalonia, Spain, and Biotechgate, Zurich, Switzerland. Biocat, a catalyzing organization dedicated to transforming the BioRegion of Catalonia into a premier life sciences and health innovation ecosystem in Europe, and Biotechgate, a pioneer in curating and marketing a global business development database tailored for the life science industry, join forces with LSN to bring the RESI global matching platform back to Europe.

The RESI Conference Series has been instrumental in connecting healthcare startups with capital investors, co-development partners, and licensing opportunities worldwide. LSN has a track record of assisting over 400 startups in raising over $5 billion through its investor database, entrepreneurial education, and RESI international partnering events. The LSN partner network, comprising ten categories of investors and licensing partners, actively seeks early-stage innovations in drugs, devices, diagnostics, and digital health for investment portfolio and product pipeline development.

The Power of RESI Partnering

The RESI Partnering platform is a dynamic tool designed to match attendees based on sector, indication, and development phase and is central to the RESI Conference Series. This innovative approach eliminates most ill-fitting meetings, ensuring startups engage with the right investors and licensing partners who align with their specific needs and goals. RESI partnering events run five times annually at life science centers worldwide. They facilitate fundraising CEOs and scientist-entrepreneurs to get out of their local region and into the international market, dramatically increasing the number of potential partners in their pipeline. Fundraising is a numbers game; a startup cannot succeed with one or two conferences yearly. LSN’s startups seek seed funding up to 2M, Series A, 2M-10M, and Series B, 10M-50M. As part of their global partnering campaign initiative, startup companies leverage RESI as a strategic launchpad to meet national and international investors and licensing partners.

“Biocat is unique in Europe because they get it; they understand that shining an international light on their startups and getting them into capital and licensing arrangements early builds the ecosystem’s future,” says Dennis Ford, CEO of Life Science Nation.

Robert Fabregat, CEO of Biocat, said, “LSN has developed a buy-side network that will bring tens of millions of Euros into the BioRegion. Biocat is confident that our rich life science technology ecosystem will capture the attention of global investors and licensing partners and enhance BioRegion’s global footprint.”

Patrik Frei, CEO of Biotechgate, stated, “The Catalan BioRegion, like many others in the European market, is not getting enough of the early-stage investor attention they deserve. Now, startups can attend RESI Europe Barcelona, meet LSN’s global partners, and plug into international RESI events in and outside Europe.”

About RESI Conference Series

RESI is a well-established go-to partnering event series for international scientist-entrepreneurs and fundraising CEOs. It offers a dynamic interactive format featuring one day of face-to-face meetings and two days of global virtual partnering. The RESI Conference Series spans North America, Europe, and Asia, receiving support from governmental agencies, regional international tech hubs, incubators, and accelerators. The 2024 RESI partnering events are scheduled as follows: RESI JPM in San Francisco on January 9th, RESI South Atlanta on March 25th, RESI Europe Barcelona on June 17th, RESI Boston on September 25th, and RESI Asia (location and partner TBD) in November.

About Life Science Nation (LSN)

Life Science Nation (LSN) created the globally recognized Redefining Early Stage Investments (RESI) Conference Series. LSN’s mission is to connect early-stage life science companies with investors and strategic partners, ultimately fostering innovation and driving advancements in the life sciences industry.

About Biocat

Biocat is a strategic stakeholder and catalyst for promoting, transforming and projecting the Catalan life sciences and health innovation ecosystem, known as the BioRegion of Catalonia. It was established in 2006 as a public-private foundation at the behest of the Government of Catalonia and the Barcelona City Council to identify the needs of the BioRegion and implement a strategy and action plan to maximize the economic and social impact of the sector.

About Biotechgate

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.